Reviewing Sanuwave Health (NASDAQ:SNWV) and Enovis (NYSE:ENOV)

Enovis (NYSE:ENOV) and Sanuwave Health (NASDAQ:SNWV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Enovis and Sanuwave Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Sanuwave Health	32.38%	1,728.10%	39.04%

Institutional & Insider Ownership

98.4% of Enovis shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 14.4% of Sanuwave Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Enovis has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Sanuwave Health has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Valuation and Earnings

This table compares Enovis and Sanuwave Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.30 billion	0.49	-$1.18 billion	($19.26)	-1.01
Sanuwave Health	$44.02 million	0.80	$11.81 million	$0.24	17.08

Sanuwave Health has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Enovis and Sanuwave Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	1	10	0	2.75
Sanuwave Health	1	1	1	0	2.00

Enovis presently has a consensus price target of $40.38, suggesting a potential upside of 106.59%. Sanuwave Health has a consensus price target of $47.00, suggesting a potential upside of 1,046.34%. Given Sanuwave Health’s higher possible upside, analysts plainly believe Sanuwave Health is more favorable than Enovis.

Summary

Sanuwave Health beats Enovis on 10 of the 14 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Sanuwave Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.